Celgene Corporation (CELG) is Reiterated by Sun Trust Rbsn Humphrey to Buy, Raises Price Target to $ 147

Celgene Corporation (CELG) was Reiterated by Sun Trust Rbsn Humphrey to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 147 from a previous price target of $145 . Sun Trust Rbsn Humphrey advised their investors in a research report released on Apr 29, 2016.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Celgene Corporation closed down -1.4 points or -1.30% at $106.15 with 59,08,642 shares getting traded on Wednesday. Post opening the session at $107.9, the shares hit an intraday low of $105.82 and an intraday high of $108.11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 5, 2016, Gilla Kaplan (director) sold 15,967 shares at $101.84 per share price. According to the SEC, on Mar 7, 2016, Michael W Bonney (director) purchased 2,000 shares at $103.01 per share price. On Dec 30, 2015, Ernest Mario (director) sold 40,000 shares at $119.36 per share price, according to the Form-4 filing with the securities and exchange commission.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Celgene Corporation

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.